Randomized, Multicenter, Open-label, Phase III Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FrA-positive Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab
Details
Randomized, multicenter, open-label, Phase 3 study of mirvetuximab
soravtansine in combination with bevacizumab versus bevacizumab
alone as maintenance therapy for patients with FRα-high recurrent
platinum-sensitive epithelial ovarian, fallopian tube, or primary
peritoneal cancers who have not progressed after second-line platinumbased
chemotherapy plus bevacizumab (GLORIOSA)
Eligibility
You can join if...
Inclusion Criteria
Patients must be <18 years of age.
Patients must have an Eastern Cooperative Oncology Group performance status of 0 or 1.
Patients must have a confirmed diagnosis of high-grade serous epithelial ovarian, primary
peritoneal, or fallopian tube cancer
Exclusion Criteria
Patients with PD while on or following platinum-based triplet therapy
Patients with prior wide-field radiotherapy affecting at least 20% of the bone marrow
Patients with > Grade 1 peripheral neuropathy per Common Terminology Criteria for
Adverse Events (CTCAE)